Phaseline

Companies › Blue Earth Diagnostics

Blue Earth Diagnostics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 1 Phase 2, 1 Phase 1, 1 Phase 4; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
fluciclovine (18F)
18F-labeled amino acid analog for PET imaging of prostate cancer
–Phase 4Prostate CancerDec 2027
[68Ga]BED003
Fibroblast activation protein (FAP) targeting PET imaging agent
FAPPhase 2Colorectal CancerFeb 2028
[18F]FPyQCP
Fibroblast activation protein (FAP) inhibitor positron emission tomography tracer
FAPPhase 1Colorectal CancerJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07569926fluciclovine (18F)Phase 4Prostate CancerOncologyDec 2027
NCT07432633[18F]FPyQCPPhase 1Colorectal CancerOncologyJan 2028
NCT07702292[68Ga]BED003Phase 2Colorectal CancerOncologyFeb 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FAP (2)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging Perspective Therapeutics

Companies built like this

Chengdu New Radiomedicine Technology SOFIE Lantheus Medical Imaging Advenchen Laboratories OSE Immunotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.